Heidelberg Pharma AG (FRA:HPHA)
Market Cap | 136.55M |
Revenue (ttm) | 3.04M |
Net Income (ttm) | -26.18M |
Shares Out | n/a |
EPS (ttm) | -0.55 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 3,910 |
Average Volume | 2,441 |
Open | 3.020 |
Previous Close | 3.080 |
Day's Range | 2.980 - 3.020 |
52-Week Range | 2.110 - 5.400 |
Beta | n/a |
RSI | 33.00 |
Earnings Date | Oct 10, 2025 |
About Heidelberg Pharma AG
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, the United States, and internationally. Its lead product candidates include HDP-101, an anti-BCMA antibody, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. The company develops HDP-102, an antibody and the compound Amanitin, which has completed preclinical development for the treatment of non-Hodgkin lymphoma; HDP-103, a proprietary ATAC candidate to treat metastatic cas... [Read more]
Financial Performance
In 2024, Heidelberg Pharma AG's revenue was 6.85 million, a decrease of -30.53% compared to the previous year's 9.86 million. Losses were -19.38 million, -4.74% less than in 2023.
Financial StatementsNews

EQS-NVR: Heidelberg Pharma AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Total Voting Rights Announcement: Heidelberg Pharma AG / Total Voting Rights Announcement Heidelberg Pharma AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with...

Heidelberg Pharma's Bold Moves in 2025's First 9 Months
Heidelberg Pharma is navigating a pivotal phase, honing in on its promising ADC candidate, HDP-101, amidst strategic shifts and financial recalibrations. Jetzt den vollständigen Artikel lesen

EQS-News: Heidelberg Pharma Reports on the First Nine Months of Financial Year 2025
EQS-News: Heidelberg Pharma AG / Key word(s): Quarterly / Interim Statement Heidelberg Pharma Reports on the First Nine Months of Financial Year 2025 09.10.2025 / 07:03 CET/CEST The issuer is solely r...

Heidelberg Pharma AG Boosts Outlook: Exciting New Guidance Revealed!
Heidelberg Pharma AG is steering its financial ship with precision, honing in on cost-saving strategies for 2025. The company has revised its sales and income expectations to a more conservative EUR 7...

EQS-Adhoc: Heidelberg Pharma AG Announces Updated Guidance
EQS-Ad-hoc: Heidelberg Pharma AG / Key word(s): Change in Forecast Heidelberg Pharma AG Announces Updated Guidance 06-Oct-2025 / 15:58 CET/CEST Disclosure of an inside information acc. to Article 17 M...

EQS-News: Heidelberg Pharma Advances to Cohort 9 in Phase I/IIa Trial of Lead ATAC Candidate HDP-101 in Multiple Myeloma
EQS-News: Heidelberg Pharma AG / Key word(s): Study results Heidelberg Pharma Advances to Cohort 9 in Phase I/IIa Trial of Lead ATAC Candidate HDP-101 in Multiple Myeloma 25.09.2025 / 13:17 CET/CEST T...

EQS-News: Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP-101 Due to Delayed Milestone Payment
EQS-News: Heidelberg Pharma AG / Key word(s): Strategic Company Decision Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP-101 Due to Delayed Milestone Paym...

EQS-Adhoc: Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP-101 Due to Delayed Milestone Payment
EQS-Ad-hoc: Heidelberg Pharma AG / Key word(s): Strategic Company Decision Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP-101 Due to Delayed Milestone Pa...

EQS-News: Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2025
EQS-News: Heidelberg Pharma AG / Key word(s): Conference Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 20...

EQS-Adhoc: Heidelberg Pharma’s Partner Telix Pharmaceuticals Gives Regulatory Update for its Imaging Agent TLX250-CDx
EQS-Ad-hoc: Heidelberg Pharma AG / Key word(s): Financing Heidelberg Pharma’s Partner Telix Pharmaceuticals Gives Regulatory Update for its Imaging Agent TLX250-CDx 28-Aug-2025 / 03:50 CET/CEST Disclo...

EQS-NVR: Heidelberg Pharma AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Total Voting Rights Announcement: Heidelberg Pharma AG / Total Voting Rights Announcement Heidelberg Pharma AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with...

EQS-DD: Heidelberg Pharma AG: Prof. Dr. Andreas Pahl, Acquisition of 90,000 shares through the exercise of 90,000 stock options under the 2011 stock option program (tranche 2; issue 2016) for ...
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 24.07.2025 / 14:23 CET/CEST The issuer is solely responsi...

EQS-News: Heidelberg Pharma Reports on First Half-Year 2025 and the Positive Course of Business
EQS-News: Heidelberg Pharma AG / Key word(s): Half Year Report Heidelberg Pharma Reports on First Half-Year 2025 and the Positive Course of Business 10.07.2025 / 07:03 CET/CEST The issuer is solely re...

EQS-News: Heidelberg Pharma Reports on the Results of the Ordinary Annual General Meeting 2025 and New Supervisory Board
EQS-News: Heidelberg Pharma AG / Key word(s): AGM/EGM Heidelberg Pharma Reports on the Results of the Ordinary Annual General Meeting 2025 and New Supervisory Board 15.05.2025 / 14:31 CET/CEST The iss...

EQS-News: Heidelberg Pharma to Present Promising New Clinical Data on its Lead ATAC Candidate HDP-101 at EHA 2025
EQS-News: Heidelberg Pharma AG / Key word(s): Conference Heidelberg Pharma to Present Promising New Clinical Data on its Lead ATAC Candidate HDP-101 at EHA 2025 14.05.2025 / 18:40 CET/CEST The issuer ...

EQS-News: Heidelberg Pharma AG: Interim Statement on the First Three Months of Financial Year 2025
EQS-News: Heidelberg Pharma AG / Key word(s): Quarterly / Interim Statement Heidelberg Pharma AG: Interim Statement on the First Three Months of Financial Year 2025 24.04.2025 / 07:16 CET/CEST The iss...

EQS-News: Heidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025
EQS-News: Heidelberg Pharma AG / Key word(s): Conference Heidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025 26.03.2025 / 09:23 CET/CEST The issuer is solel...